{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-22-008514","form_type":"8-K","ticker":null,"cik":"0001629205","company_name":"Innovation1 Biotech Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.493480+00:00","generated_at":"2026-06-21T20:25:33.492056+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Innovation1 Biotech sells Mioxal® assets to Ingenius Biotech for stock and royalties","bullets":["Company transferred all Mioxal-related assets including IP to Ingenius Biotech S.L.","Consideration includes 350,000 shares of Innovation1 common stock to Ingenius.","Ingenius to pay $100,000 upon first sale/commercialization and a 5% royalty on net sales.","Ingenius releases Innovation1 from all Mioxal liabilities and provides indemnification.","Transaction completed on November 7, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-22-008514","json":"https://secwatch.observer/filing/0001477932-22-008514.json","markdown":"https://secwatch.observer/filing/0001477932-22-008514.md","text":"https://secwatch.observer/filing/0001477932-22-008514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1629205/000147793222008514/0001477932-22-008514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1629205/000147793222008514/ivbt_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:25:33.492056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf3229394107ed153c831026cf205a2db3f00dc5","claim":"Innovation1 Biotech Inc. completed a disposition involving Ingenius Biotech S.L. (closed 2022-11-07).","evidence_excerpt":"On November 7, 2022, Innovation1 Biotech Inc., a Nevada corporation (the “Company”), completed the disposition (the “Disposition”) of all of the assets, including intellectual property assets, relating to Mioxal®, a nutraceutical complex composed of essential amino acids, natural coenzymes and minerals, to Ingenius Biotech S.L., a corporation organized under the laws of Spain (“Ingenius”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1629205/000147793222008514/0001477932-22-008514-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Ingenius Biotech S.L."},{"label":"Closing","value":"2022-11-07"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}